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Short Communication:
Peptide-based immunotherapy of experimental
autoimmune encephalomyelitis without anaphylaxis
Melanie D. Leech, Chen-Yen Chung, Abigail Culshaw and
Stephen M. Anderton
University of Edinburgh, Institute of Immunology and Infection Research, School of
Biological Sciences, Edinburgh, UK
Administration of peptide antigens in tolerogenic form holds promise as a specific
treatment for autoimmune and allergic disorders. However, experiments in rodent
autoimmune models have highlighted the risk of anaphylaxis in response to systemic
peptide application once the aberrant immune response is underway. Thus, mice with
clinical signs of experimental autoimmune encephalomyelitis (EAE) or diabetes have
been reported to suffer fatal anaphylaxis upon administration of native autoantigenic
peptides. Clearly, this might represent a significant barrier to the use of synthetic
peptides in the treatment of ongoing human autoimmune conditions. Here we describe
the development of an altered peptide ligand (APL) engineered to prevent anaphylaxis
(no antibody binding) whilst retaining the ability to silence pathogenic myelin-reactive
T lymphocytes. Administration of the APL to mice with an ongoing anti-myelin immune
response did not cause anaphylaxis, but led to complete protection from the subsequent
induction of EAE and, when given during ongoing EAE, led to a rapid remission of
clinical signs. The approach of removing antibody recognition whilst maintaining the
desired functional effect (in this case Tcell tolerance) may be of value in other situations
in which there is a risk of triggering anaphylaxis with peptide-based drugs.
Introduction
We and others have administered synthetic peptides
containing T cell epitopes in soluble form to induce
immune tolerance and prevent the development of
various rodent models of autoimmune disease and
several clinical trials are underway in humans [1–3].
Rodent studies have overwhelmingly focused on indu-
cing tolerance in naive T cells, before exposure to the
autoantigen in immunogenic form. In humans, the
requirement is to switch off an autoaggressive response
that is fully underway. Concern has been raised because
the ongoing response can involve IgE antibodies capable
of binding the synthetic peptides upon systemic
administration, therefore leading to fatal anaphylactic
responses in rodents [4–7]. This has particularly been
shown in EAE, the T cell-driven mouse model of MS.
Clearly, this is a potential complication that must be
considered in the human setting. Indeed, a previous
peptide-based trial inMSwas halted because of evidence
of developing hypersensitivity [8].
How can the risk of peptide-induced anaphylaxis be
overcome? Based on studies using altered peptide ligand
(APL), it is well established that T cell recognition of
peptide epitopes is focused upon a few TCR contact
residues [9]. We reasoned that anti-peptide antibody
responses might similarly be focused on particular
residues within the peptide. If the TCR contact and
antibody contact residues were sufficiently diverse, we
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might be able to generate an APL that retained TCR
binding, but not antibody binding, and therefore could
induce tolerance but not anaphylaxis in vivo (TCR-
binding is required to provide Tcell tolerance). Here, we
describe the use of such an APL to achieve profound
tolerance in the face of an ongoing anti-myelin T cell
response.
Results and discussion
Identification of antibody-binding residues with
peptide 35–55 of MOG
For this study, we used EAE induced in C57BL/6 mice by
immunization with the peptide 35–55 (p35–55) of
myelin oligodendrocyte glycoprotein (MOG) [10]. Fatal
anaphylaxis has been previously reported in this model
when giving soluble p35–55 after EAE has developed [4,
6], and our early attempts to induce tolerance with the
wild-type p35–55 were hampered by this effect (four of
six mice requiring euthanasia).
We therefore examined requirements for antibody-
binding using sera from mice that had been immunized
with p35–55. Surprisingly, we were unable to detect
anti-p35–55 IgE in these sera, even after IgG-depletion
(data not shown). However, significant titres of anti-
p35–55 IgG1were consistently observed (Fig.1A). Using
a competition ELISA, we were able to block binding of
IgG1 to p35–55 by pre-incubation with the same peptide
(Fig. 1B and C). We next utilized two panels of MOG
peptides that we had generated for analysis of T cell
activation in response to MOG. The first panel were
overlapping 15mers covering the 35–55 sequence and
shifting by one residue (i.e. 30–44, 31–45, etc, through
to 46–60). The second panel were 16mer APL based on
the 35–50 sequence with Ala substitutions at each
individual residue (35Ala, 36Ala, etc). The 35–50
sequence was chosen because the core epitope for
T cell recognition has been described as residues 40–48
[11]. These peptides were used in the competition ELISA
to define the requirements for antibody binding (i.e. a
positive signal in the ELISA, indicating that the peptide
used for pre-incubation could not bind to the anti-
p35–55 antibodies).
Figure 1. Identification of MOG35–50 (37Ala) as an APL that does not bind antibody. Binding of IgG1 to the p35–55 peptide was
measured by ELISA (A–C). Pooled sera frommice that hadundergone EAE (i.e. after immunizationwith p35–55 inCFA, togetherwith
administrationof pertussis toxin, Pool I), or thathadbeen immunizedwithp35–55without EAE induction (i.e.withCFA, butwithout
the use of pertussis toxin, Pool II), were titrated into a direct ELISA for p35–55 binding and the presence of IgG1 detected (A). Also
shown isbindingbyan individual EAEserumsampleand lackofbindingbynon-immunepooledsyngeneic serum.Stronglybinding
individual sera (B, C) were pre-incubatedwith increasing doses of peptide (p35–55, p35–50, or ovalbumin 323–339 as a control) and
inhibition of subsequent binding to p35–55 was calculated. Two serotypes were identified based on the ability of p35–50 to inhibit
binding. Sera of type A or B were tested for blocking of p35–55-antibody binding by a single dose (30 lg/mL) of overlapping MOG
peptides covering residues 30–60 (D, E). Sera of type A were preincubated with 30 lg/mL of p35–50, or APL thereof (F).
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The first interesting observation using individual sera
was that there were two serotypes; type A sera could
bind to the wild-type p35–50 peptide (Fig. 1B), whereas
type B sera could not (Fig. 1C). We next used the 15mer
overlapping peptides to more precisely map the regions
recognized by the type A and type B sera. Serotype A
focused on residues 35–44 (Fig. 1D), whereas serotype B
focused on residues 42–52 (Fig. 1E). Neither of these
serotypes seemed to be dominant and as yet it is unclear
what determines the serotype that an individual mouse
will display.
We next tested the APL based on p35–50 for antibody
binding. We could not use these APL to test for binding
to type B sera, because these did not bind the native
35–50 peptide. Testing type A sera revealed five APL
(36Ala, 37Ala, 39Ala, 43Ala and 49Ala) that failed to
bind the sera (Fig. 1F).
The 37Ala APL induces T cell tolerance and does
not provoke anaphylaxis
To identify a peptide that did not cause anaphylaxis in
vivo we chose to pursue the 37Ala APL because it
involved alteration of a residue outwith the published
core Tcell epitope of 40–48 [11]. Furthermore, we found
that this APL could stimulate p35–55-reactive T cells in
vitro, with a dose response essentially identical to that of
p35–55 (Fig. 2A). To test the ability of this peptide to
induce T cell tolerance, we gave a single i.v. injection of
the peptide in saline, either before or after immuni-
zation with p35–55 in CFA. The 37Ala APL proved as
effective as the wild-type p35–55 peptide at inducing
naive T cell tolerance in vivo when given in advance of
p35–55 immunization (Fig. 2B and C).
We next gave an i.v. injection of the 37Ala APL, or a
control APL, 38Ala that did bind anti-p35–55 antibodies
(Fig. 1F), to mice that had been immunized 4 weeks
previously with p35–55 in CFA and were sero-positive
for anti-p35–55. Two of three mice that received the
38Ala APL showed anaphylaxis and were euthanised
immediately. In contrast, none of the mice that received
37Ala showed signs of anaphylaxis. By sampling 7 days
after this i.v. injection, we could therefore test whether
these mice had become tolerant to p35–55. Compared
with their PBS-treated counterparts, the mice that had
received 37Ala, gave proliferative responses that were
around 10-fold less sensitive to p35–55 (Fig. 2D) and
IFN-c responses that were approximately 100-fold less
sensitive (Fig. 2E). These data suggested that a single
dose of the 37Ala peptide had a marked tolerogenic
effect on the ongoing anti-MOG T cell response but,
crucially, did not cause anaphylaxis.
Finally, we tested whether the 37Ala APL could
influence the course of EAE. To test p35–55-immune
mice before re-immunizing to induce EAE, we immuni-
zed with p35–55 in incomplete Freund's adjuvant
supplemented with CpG oligonucleotide. This primary
immunization protocol reliably induces strong anti-
p35–55 T cell responses but not EAE, and allows EAE to
develop subsequently in response to immunization with
p35–55 in CFA with accelerated disease kinetics,
indicating the presence of antigen-experienced cells
generated by the primary immunization (Chung et al.,
manuscript in preparation). We gave PBS, with or
without the 37Ala APL, 24 days after the primary
immunization. Seven days later, we immunized for a
second time to induce EAE and found that the 37Ala-
treated group were completely protected from disease
(Fig. 3A). Upon ex vivo analysis, the mice that were
protected by 37Ala treatment showed a complete
absence of IFN-c production (Fig. 3B) and IL-17
production (not shown) as well as markedly reduced
proliferation (not shown) in recall responses to p35–55.
The above experiments showed that ongoing T cell
response could be abrogated leading to protection from
EAE upon subsequent secondary immunization. To test
for an effect on the progression of active disease, we
induced EAE with a primary immunization with p35–55
in CFA.We then gave a single i.v. dose of 300 lg 37Ala or
Figure 2. Tolerogenic properties of the MOG35–50 (37Ala) APL.
Proliferation of a p35–55-reactive CD4+ T cell line was tested
after culture with p35–55, or the p35–50(37Ala) APL (A). Mice
were given a single 300-lg dose of soluble p35–55, or p35–50
(3Ala), or PBS alone intravenously, 7 days before immunization
with p35–55 in CFA (CFA) (B, C). Ten days after immunization,
draining inguinal and para-aortic lymph nodes were removed
and tested for recall responses to p35–55 as measured by
proliferation (B) or IFN-c production (C). (D, E) Mice were
immunized with p35–55 in CFA and 28 days later received
soluble p35–50 (37Ala) or PBS as above. Seven days after peptide
injection, spleens were removed and tested individually for
recall proliferation (D) and IFN-c production (E) to p35–55. Each
tolerance experiment shown is one of two experiments giving
consistent results; three mice per group were used.
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PBS when clinical signs were in the ascendancy
(day 12). Mice that received 37Ala showed a striking
reduction in clinical signs 24 h later and this was
maintained through the subsequent disease course
(Fig. 3C). Analysis of splenocytes at day 26 revealed a
reduced ability to produce IFN-c in the 37Ala-treated
group (Fig. 3D). The rapid effect that 37Ala had on EAE
suggested that it may be acting on effector T cells within
the target organ. To test this, we sampled CNS 3 days
after giving 37Ala or PBS and found a reduced number
of infiltrating CD4+ cells in the 37Ala-treated group
(Fig. 3E and F). The protective effects of 37Ala on
clinical EAE score were lost when a lower (200 lg) dose
was administered, even though splenocytes from mice
treated in this way showed reduced p35–55-induced
recall responses (proliferation and IFN-c production,
data not shown). This suggests that for the peptide to
work in active disease, a threshold level of peptide-MHC
complexes needs to be achieved within the CNS.
Thus, in 37Ala we have identified a highly effective
therapeutic APL that removes the risk of anaphylaxis.
This allowed us to show that, the administration of
peptide in soluble form could provoke profound
tolerance to autoantigen either when given before a
primary immunization, when given between primary
and secondary immunizations and even when given at
the height of active EAE. This latter observation is
particularly pertinent, as we found no adverse clinical
effects that could be attributed to excessive cytokine
release from Tcells in the CNS in response to the soluble
peptide. The basic paradigm for peptide-induced
tolerance in naive T cells is that antigen presentation
by steady state DC leads to an abortive activation and
T cell death due to insufficient survival signals [12]. It
may well be that the tolerance induced here after
immunization has a different basis, perhaps activation-
induced cell death of differentiated effector T cells (a
possibility supported by reduced CD4+ cell numbers in
the CNS after peptide administration). Clarification of
this will require further extensive analyses that are
beyond the scope of this report.
In the clinical setting, repeated administration of
peptides to MS patients has provoked anti-peptide IgE
and IgG1 responses and hypersensitivity leading to the
termination of that particular trial [8]. We could
measure anti-p35–55 IgG1, but not IgE. It is unclear
whether the anaphylaxis seen against p35–55 was the
result of IgE at levels below detection, or because of the
IgG1 that was evident. Although IgG1 is capable of
binding to mast cells and could provide the anaphylactic
trigger [13], a previous report using the same EAEmodel
as we have used here has clearly implicated IgE and
ruled-out IgG1 [6]. In potential human studies, where
IgE might be more easily detected, this is likely to be the
isotype that should be studied.
Many studies have used APL to alter T cell responses
in vitro and in vivo, including the modulation of
autoimmune models [14–16]. However, to our know-
ledge, this is the first study to show that we can use APL
to define antibody-peptide binding, allowing peptide-
based therapeutic immune tolerance in the absence of
anaphylaxis.
Concluding remarks
Here, we have addressed two key questions. First, can an
ongoing autoimmune T cell response be silenced
sufficiently to control disease (i.e. can peptides truly
be used as treatments rather than prophylactically)?
Second, can the previously identified risk of anaphylaxis
Figure 3. MOG35–50(37Ala) given after T cell priming protects
mice from EAE. (A) Mice received a primary immunizationwith
p35–55 in incomplete Freund's adjuvant supplemented with
60 lg CpG. Twenty-four days later mice received soluble
p35–50(37Ala), or PBS, as above. Seven days after peptide
injection, mice were given a secondary immunization with
p35–55 in CFA to induce EAE. (B) Splenocytes were taken from
EAE mice shown in (A) 28 days after the secondary immuniza-
tion and tested individually for recall IFN-c production in
response to p35–55. (C–F) EAE was induced by a primary
immunization with p35–55 in CFA. Twelve days later, mice
received either PBS or p35–50(37Ala) i.v. (arrows) and effects on
EAE were monitored (C, E). Individual splenocyte populations
were tested for recall IFN-c responses to p35–55 at day 26 (D). In
the experiment shown in (E), mice were sacrificed on day 15
andnumbers of infiltratingCD4+ cells in theCNSwere assessed
by FACS analysis. The experiment (four mice per group) shown
in (A, B) is one of two that gave consistent results. Data in (C–F)
are from two of four experiments (three to fourmice per group)
that gave consistent results. For (A) and (C), disease scoreswere
significantly different between the PBS- and 37Ala-treated
groups (p<0.001 in each case). Note: in these experiments, wild
type p35–55 was not given in soluble form because our
preliminary experiments showed that this peptide provoked
anaphylaxis when injected after immunization.
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be avoided by understanding the requirements for
peptide interaction with antibody? The data presented
here give a positive answer to both these questions. The
use of peptides as small molecule drugs is a developing
field [17] and anti-peptide anaphylaxis could be a real
complication here. Therefore, variant peptides that can
be shown to have the desired functional efficacy without
binding to antibodies might have a more general
relevance beyond immunotherapy.
Materials and methods
Mice, antigens, and immunizations
C57BL/6 mice were bred under specific pathogen-free
conditions at the University of Edinburgh. The 6–8-week-
old, sex-matched mice were used for all experiments. Peptides
p35–55 and p35–50 of MOG and 323–339 of chicken
ovalbumin were synthesized by the Advanced Biotechnology
Centre, Imperial College (London, UK). Two panels of peptides
were generated. The first panel were 15mers that shifted by
one residue and covered MOG 30–44 to 46–60. The second
panel were APL based on p35–50, with Ala substitutions at
individual residues (35Ala, 36Ala, etc, through to 50Ala).
These panels of peptides were synthesized by the laboratory of
Professor D. Wraith, University of Bristol, UK. Unless otherwise
stated, mice were immunized with 100 lg of p35–55
emulsified in complete Freund's adjuvant (CFA, Sigma, Poole,
UK). A total of 100 lL of emulsion was injected s.c., 50 lL into
each hind leg. Primed lymphoid populations were derived
either from spleens, or from draining inguinal and para-aortic
lymph nodes at the times indicated.
pMOG-specific IgG1 ELISA
Microtitre plates were coated with 5 lg/mL p35–55 diluted in
0.05 M carbonate bicarbonate buffer (pH 9.6) prior to
blocking nonspecific binding with 3% BSA in PBS. Sera were
double diluted through eight consecutive dilutions from an
initial 1 in 5 dilution in PBS-T. Bound antibody was detected
using alkaline phosphatase labelled goat anti-mouse IgG1 (c1
chain specific; Southern Biotech) and developed using pNNP
substrate (Southern Biotech).
Competition ELISA for inhibition of IgG1-p35–55
binding
Microtitre plates were coated with 5 lg/mL p35–55 and
blocked as above. Sera were diluted to a final dilution of 1 in 40
in PBS-T (PBS with 0.1% Tween 20). Inhibition of antibody
binding to p35–55 was tested by pre-absorption at 4C for
30 min with graded doses of peptide, or with 30 lg/mL of
either the p35–50 APL, or the overlapping peptides. Specificity
of inhibition was determined by pre-incubation with peptide
323–339 of ovalbumin. Bound IgG1 was detected as above.
Tolerance induction and assessment of lymphoid recall
responses
Mice received 300 lg of peptide in 0.2 mL PBS (or PBS alone)
i.v. at the indicated time before or after immunization with
p35–55. Lymphoid-cell suspensions were cultured in 96-well
flat-bottom microtitre plates (Becton Dickinson, Oxford, UK)
at 6  105 lymph node cells/well, or 8  105 splenocytes/well,
using X-vivo 15TM serum-free medium (BioWhittaker, Maiden-
head, UK) supplemented with 2 mM L-glutamine and 5 
10–5 M 2-ME (all from Invitrogen Life Technologies, Paisley,
UK). Cultures were stimulated with a dose range of p35–55 for
48 h prior to addition of [3H]thymidine (0.5 lCi/well)
(Amersham, Amersham, UK). After further 18 h, cultures
were harvested and thymidine incorporation was measured
using a liquid scintillation b-counter (LKB Wallac, Turku,
Finland). Results are expressed as mean cpm of triplicate
cultures. Supernatants from similar 72-h cultures were tested
for p35–55-induced production of IFN-c and IL-17 by ELISA.
p35–55-reactive T cell line
The PP.TCL CD4+ T cell line was generated using repeated
restimulation and expansion cycles as described previously
[18]. Proliferation assays were performed using flat-bottom
200 lL microtitre wells (Becton Dickinson). T cells (2  104/
well) were cultured with irradiated (30 Gy) syngeneic
splenocytes (3  105/well) in the presence or absence of
peptide antigen for a total of 72 h. Cultures were pulsed for the
final 16 h with [3H]thymidine and incorporation measured as
above.
Induction and assessment of EAE
EAEwas induced using a previously described protocol [19]. In
some experiments this was modified as follows. Mice were first
immunized in one hind leg with 50 lg of p35–55 in 50 lL
incomplete Freund's adjuvant supplemented with 60 lg of
CpG oligonucleotide (MWG Biotech, London, UK). At the
indicated times, mice then received either 300 lg of the
p35–50(37Ala) in PBS or PBS alone intravenously. EAE was
then induced by a second immunizationwith 100 lg p35–55 in
50 lL CFA into the other hind leg. Mice also received 200 ng
pertussis toxin (Health Protection Agency, Dorset, UK) i.p. in
0.5 mL PBS on the same day and 2 days later. Group sizes were
4–6 per treatment group.
Clinical signs of EAE were assessed using the following
scoring index: 0, no signs; 1, flaccid tail: 2, impaired righting
reflex and/or impaired gate; 3, partial hind leg paralysis; 4,
total hind leg paralysis; 5, hind and fore leg paralysis; 6,
moribund or dead. Differences in total disease burden between
groups were determined using the Mann-Whitney U-test. CNS
mononuclear cell samples (from brain and spinal cord) were
prepared and stained for CD4-expression as described
previously [19].
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